# Writer-Critic Review — `paper/sections/intro.tex`

**Project:** phage_therapy_mdr_pseudomonas
**Phase:** Execution (STRICT severity)
**Paper type:** Descriptive/measurement systematic review + meta-analysis of proportions (IMRaD structure per `.claude/references/domain-profile.md`, not econ working-paper format)

## Score: 95/100

## Category-by-category findings

**1. Claims-evidence alignment (highest priority) — PASS, no discrepancies found.**
Checked every numerical/factual claim against `results_summary_...md`, the two decision records, and the annotated bibliography — all match exactly (86.1% CI 68.2-94.7%, "at least eight further systematic reviews," Liu 2025's 130-study IPD meta-analysis, the 0-1 qualifying comparative study finding, the confirmed monotherapy-stratum absence).

**2. No efficacy overclaiming — PASSES, and does so well.** The Introduction explicitly frames 86.1% as coming from "a compassionate-use population selected for refractory infection after antibiotic failure" and states it "should not be read as evidence that phage therapy outperforms, or underperforms, any comparator." This is the single most important check for this paper type and it is handled correctly.

**3. Citation validity — PASS.** All six keys resolve to real, correctly detailed `Bibliography_base.bib` entries, each with PMID verification notes. `\textcite`/`\parencite` used correctly per convention.

**4. Contribution honesty — PASS.** The pivot from comparative-effect design to proportion-pooling is narrated accurately and matches the discovery/strategy decision records — no rosier retelling.

**5-6. LaTeX quality / writing quality — one recurring minor issue (fixed).**
- Em-dash spacing was inconsistent (asymmetric hybrid style, 4 occurrences) — corrected to tight em-dash style (`text---text`) throughout.
- No hedging language, no AI-writing tells. Species names and percent signs correctly escaped/italicized.
- Word count ≈ 484-493 words, within the 400-600 word clinical convention target.

**7. PRISMA setup — PASS.** No Methods content front-loaded; PRISMA/protocol detail correctly deferred.

## Critical issues
None. No broken citations, no numeric mismatches, no efficacy overclaiming.

## Recommendation
Em-dash spacing fixed post-review. Score clears both the 80 commit gate and 90 PR gate.
